- Home
- CAL vs AUPH Comparison
CAL vs AUPH Comparison
Compare CAL & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAL
- AUPH
- Stock Information
- Founded
- CAL 1878
- AUPH 1993
- Country
- CAL United States
- AUPH Canada
- Employees
- CAL N/A
- AUPH N/A
- Industry
- CAL Shoe Manufacturing
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- CAL Consumer Discretionary
- AUPH Health Care
- Exchange
- CAL Nasdaq
- AUPH Nasdaq
- Market Cap
- CAL 446.5M
- AUPH 1.1B
- IPO Year
- CAL N/A
- AUPH 1999
- Fundamental
- Price
- CAL $14.69
- AUPH $8.86
- Analyst Decision
- CAL Hold
- AUPH Strong Buy
- Analyst Count
- CAL 1
- AUPH 2
- Target Price
- CAL $14.00
- AUPH $11.50
- AVG Volume (30 Days)
- CAL 910.2K
- AUPH 2.0M
- Earning Date
- CAL 09-11-2025
- AUPH 07-31-2025
- Dividend Yield
- CAL 1.93%
- AUPH N/A
- EPS Growth
- CAL N/A
- AUPH N/A
- EPS
- CAL 2.43
- AUPH 0.27
- Revenue
- CAL $2,677,706,000.00
- AUPH $247,295,000.00
- Revenue This Year
- CAL N/A
- AUPH $12.15
- Revenue Next Year
- CAL $3.48
- AUPH $18.31
- P/E Ratio
- CAL $6.05
- AUPH $33.08
- Revenue Growth
- CAL N/A
- AUPH 29.20
- 52 Week Low
- CAL $12.09
- AUPH $5.20
- 52 Week High
- CAL $44.51
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- CAL 58.35
- AUPH 64.10
- Support Level
- CAL $12.14
- AUPH $7.36
- Resistance Level
- CAL $15.02
- AUPH $9.10
- Average True Range (ATR)
- CAL 0.67
- AUPH 0.44
- MACD
- CAL 0.30
- AUPH 0.10
- Stochastic Oscillator
- CAL 88.74
- AUPH 89.53
About CAL Caleres Inc.
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - famous Footwear and Brand Portfolio. The famous Footwear segment is comprised of its famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The famous Footwear segment operated around 846 stores at the end of 2024. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. Geographically, the company generates the majority of its revenue from Domestic operations.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.